Domov › Atopični dermatitis (ekcem) › Arkansas
Klinične študije za Atopični dermatitis (ekcem) v Arkansas
8 študij za Atopični dermatitis (ekcem) išče udeležence na lokacijah v Arkansas.
Mesta v Arkansas
Uradno besedilo študije (angleško)
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Fort Smith
Vključevanje udeležencevFaza 2
Starost 18–100 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Hot Springs
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07298395A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Arkansas Research Trials, North Little Rock
Vključevanje udeležencevFaza 3
Starost 2–11 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Dermatology Trial Associates, Inc, Bryant
Vključevanje udeležencevFaza 2
Starost 18–65 · Vsi spoli · Posodobljeno 28. avg. 2026 · NCT07599813A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Applied Research Center and Wellness Clinic /ID# 268547, Little Rock
Vključevanje udeležencevFaza 3
Starost 2–11 · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT06461897A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, North Little Rock
Vključevanje udeležencevFaza 3
6 Months – 11 Years · Vsi spoli · Posodobljeno 7. jul. 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville
Vključevanje udeležencevFaza 3
Starost 18–63 · Vsi spoli · Posodobljeno 6. jul. 2026 · NCT06389136A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
- Arkansas Research Trials, North Little Rock
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 19. sep. 2025 · NCT06055361Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.